Extended vs. Intermittent Meropenem Infusion in Sepsis Patients in the ICU

Sponsor
Assiut University
Study ID
NCT07398703
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Sepsis
  • Septic Shock

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Extended beta-lactam antibiotics — DRUG
    Group A will be receiving extended infusion of beta-lactam antibiotic over 4 hours.
  • Intermittent Beta-lactam antibiotics — DRUG
    Group B will be receiving intermittent infusion of beta-lactam antibiotic over 30 minutes.

Study Details

This observational study compares extended versus intermittent beta-lactam infusion in sepsis patients, assessing survival, clinical cure rates, and practical ICU challenges. The findings will guide optimal antibiotic protocols, potentially improving sepsis outcomes through precision dosing strategies.

Key Dates

First listed
Feb 10, 2026
Start date
Oct 31, 2027
Status verified
Aug 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
90 participants (estimated)

Arms

  • Arm: Group A
    Extended infusion of beta-lactam antibiotics
  • Arm: Group B
    Intermittent infusion of beta-lactam antibiotics

Primary Outcome Measure

All-cause mortality at 28 days from the date of randomization. [ Time Frame: Baseline and 28 days ]

Central Contacts

Related Studies